Welcome to our dedicated page for Orasure Tech SEC filings (Ticker: OSUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OraSure Technologies Inc. filings document the regulatory record of a Nasdaq-listed diagnostics and sample management company. Its Form 8-K reports cover quarterly and annual operating results, Regulation FD presentations, business developments, board changes, and material agreements tied to shareholder and governance matters.
OraSure's proxy materials disclose director elections, executive compensation, board committee structure, shareholder voting matters and governance proposals, including matters related to board classification. The filings also identify the company's common stock listing, capital structure, risk and governance disclosures, and formal records for cooperation agreements, director appointments, resignations and investor communications.
OraSure Technologies Inc. is the subject of an amended beneficial ownership filing by Altai Capital Management and related parties, who report owning 3,740,836 shares of common stock, representing 5.21% of the outstanding class. The reporting persons have shared voting and shared dispositive power over all of these shares and no sole voting or dispositive power.
Through this Amendment No. 2, the group discloses that on January 15, 2026, Osprey notified OraSure that it intends to nominate Rishi Bajaj and John Bertrand for election to the board at the company’s 2026 annual stockholder meeting. Osprey also plans to present a proposal asking the board to declassify itself so that all directors stand for election annually, and the reporting persons state they intend to solicit proxies in support of these director nominees and the declassification proposal.
OraSure Technologies (OSUR) filed its Q3 2025 10‑Q showing lower sales and wider losses. Net revenues were $27.085M (down 32% year over year), driven by declines in HIV diagnostics and Sample Management Solutions, plus the wind‑down of risk assessment testing and sharply lower COVID‑19 demand. Gross margin was 43.5%, slightly above last year on mix and higher non‑product revenue.
The company reported an operating loss of $16.1M and a net loss of $13.712M for the quarter. Research and development rose to $10.106M (up 80%) as clinical trials advanced for the CT/NG test acquired with Sherlock. For the nine months, net revenues were $88.258M (down 41%) with an operating loss of $51.866M.
Cash and cash equivalents were $216.478M at September 30, 2025 after a $51.285M year‑to‑date decrease, including $10.001M used to repurchase shares under a $40.0M authorization. Non‑product revenues increased on funded R&D tied to Sherlock and BARDA contracts. Subsequent to quarter‑end, the company signed an agreement to acquire BioMedomics for an upfront $4.0M in cash, plus contingent consideration.
OraSure Technologies (OSUR) reported that it issued a press release announcing its consolidated financial results for the quarter ended September 30, 2025. The company also furnished that release as Exhibit 99.1.
Management hosted a webcast with analysts and investors on November 5, 2025 to discuss results and business developments, and furnished an investor presentation as Exhibit 99.2. The materials were provided under Items 2.02 and 7.01 and are described as furnished, not filed.
OraSure Technologies (OSUR) announced Board changes. On October 28, 2025, Mara G. Aspinall resigned as director and chair of the Board, effective immediately, and the company stated her resignation was not due to any dispute or disagreement. The Board appointed John P. Kenny, a current director, as the new chair.
The Board also appointed Steven Boyd as a Class II director effective October 28, 2025, with a term through the 2026 Annual Meeting. He was deemed independent under Nasdaq rules and Rule 10A-3 and will serve on the Audit and Nominating & Corporate Governance Committees. Under the director compensation policy, he will receive time-vested restricted shares valued at $100,000 that vest in two years.
Dimensional Fund Advisors LP reported ownership of 3,636,260 shares of OraSure Technologies Inc common stock, representing 5.0% of the outstanding class. Dimensional states it has sole voting power for 3,560,315 shares and sole dispositive power for 3,636,260 shares, while disclaiming beneficial ownership because the shares are held by various funds it advises.
The filing is a Schedule 13G/A indicating a passive, investment-adviser position rather than an activist stake. The report explains the holdings arise from Dimensional’s advisory roles to registered investment companies, commingled funds, group trusts and separate accounts and notes no group affiliation or parent-subsidiary acquisition activity is claimed.
OraSure Technologies (OSUR) director John P. Kenny received 6,118 restricted shares on 09/24/2025 under the company's Stock Award Plan in lieu of cash fees. The shares were granted at an indicated price of $3.269 and vest immediately, increasing Mr. Kenny's beneficial ownership to 153,322 shares. The Form 4 was signed by an attorney-in-fact on 09/26/2025. The filing records this as a non-derivative acquisition and specifies the grant was made under the company plan as compensation for director fees.
Altai Capital Management and related parties disclosed a 5.13% stake in OraSure Technologies (OSUR), reporting ownership of 3,748,836 shares. The position is held for accounts managed by Altai, acquired with about $11,461,291 of working capital. The filing states the stake was purchased for investment purposes and that Altai may engage with OraSure management, the board, shareholders or other parties about matters including strategy, governance and capital structure, but currently has no contracts or formal plans to effect specific changes. All shares are reported as shared voting and dispositive power; no sole voting power is claimed.
Earnest Partners, LLC filed Amendment No. 1 to a Schedule 13G reporting its holdings of OraSure Technologies, Inc. (OSUR) common stock. The amendment states Earnest Partners beneficially owned 795 shares, representing 0.0% of the class, and that it ceased to own more than 5% of the issuer as of December 31, 2022. The filing notes it was submitted late due to an inadvertent oversight and affirms the shares were not held with any control intent. The amendment is signed by the firm’s Chief Compliance Officer on 09/03/2025.
Earnest Partners, LLC filed Amendment No. 1 to a Schedule 13G reporting its holdings of OraSure Technologies, Inc. (OSUR) common stock. The amendment states Earnest Partners beneficially owned 795 shares, representing 0.0% of the class, and that it ceased to own more than 5% of the issuer as of December 31, 2022. The filing notes it was submitted late due to an inadvertent oversight and affirms the shares were not held with any control intent. The amendment is signed by the firm’s Chief Compliance Officer on 09/03/2025.
OraSure Technologies Chief Financial Officer Kenneth J. McGrath reported a Form 4 disclosing a tax-withholding disposition tied to the vesting of restricted stock. On 08/08/2025 the filing shows 12,524 shares were withheld to satisfy tax obligations at a reported price of $2.78 per share. After the withholding he beneficially owned 448,463 shares directly.
The filing is a routine Section 16 disclosure related to compensation vesting rather than an open-market sale. The explanation on the form explicitly states the shares were withheld to pay the tax liability associated with vested restricted shares, indicating this transaction reflects tax withholding on compensation.